🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 06 Jul 2026 · EMA CTIS official data

Clinical Trials in Czechia

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

81
Recent authorisations
50
Phase III trials
Czechia
Selected country
Phase I Cardiovascular Diseases Authorised 02/07/2026
Bioequivalence Study of Dapagliflozin 10 mg
Not applicable (submitted trial is a BE study in healthy participants)
Vipharm S.A. · 40 participants
📍 Czechia
2026-526840-10-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"
Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 181 participants
📍 Spain · Czechia · France · Italy · Germany · Greece
2025-523815-12-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 01/07/2026
A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)
Asthma
AstraZeneca AB · 5 participants
📍 Czechia
2025-524914-26-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S · 189 participants
📍 Finland · Belgium · France · Denmark · Austria · Germany · Italy · Czechia · Norway
2025-522167-15-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc. · 128 participants
📍 Greece · France · Italy · Belgium · Denmark · Germany · Czechia · Portugal · Austria
2025-521769-29-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 29/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 40 participants
📍 Germany · Bulgaria · Belgium · Spain · Greece · Italy · Czechia
2025-524855-30-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 29/06/2026
A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
Non-Muscle Invasive Papillary Bladder Cancer
Hamlet BioPharma AB · 169 participants
📍 Czechia
2026-525531-16-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 23/06/2026
Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone
Small for gestational age (SGA) and idiopathic short stature (ISS)
Schneider Children's Medical Center Of Israel · 95 participants
📍 Greece · Poland · France · Czechia
2025-523832-38-00 on CTIS ↗
Phase III Immune System Diseases Authorised 22/06/2026
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Hereditary Angioedema
Adarx Pharmaceuticals Inc. · 45 participants
📍 Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia
2025-521353-16-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC · 467 participants
📍 Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc. · 228 participants
📍 Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica
Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement · 177 participants
📍 France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain
2024-511296-15-00 on CTIS ↗
Phase I Reproductive and Urinary Physiological Phenomena Authorised 12/06/2026
Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.
Healthy subjects
Pevisal Group Farmaceutici S.r.l. · 24 participants
📍 Czechia
2025-524871-22-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 10/06/2026
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC)
Eli Lilly & Co. · 104 participants
📍 Latvia · Portugal · Greece · France · Czechia · Italy · Poland · Slovakia · Hungary · Croatia · Lithuania
2025-524404-29-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)
Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc. · 496 participants
📍 Norway · Czechia · Portugal · Austria · Poland · France · Spain
2025-522176-86-01 on CTIS ↗
Phase III Neoplasms Authorised 08/06/2026
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC)
Zai Lab (US) LLC · 234 participants
📍 Belgium · Czechia · Germany · Denmark · Greece · Netherlands · Poland · Spain · Austria · Italy · France
2025-522818-23-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 08/06/2026
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Pfizer Inc. · 318 participants
📍 Spain · Germany · Poland · Czechia · Greece · Italy · Bulgaria · France · Hungary
2024-518587-12-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/06/2026
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 250 participants
📍 Austria · Slovakia · Portugal · Czechia · Hungary · Spain · France · Denmark · Italy · Croatia
2025-524894-17-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 04/06/2026
Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions
Not applicable (submitted trial is a bioavailability trial in healthy participants).
Laboratorios Cinfa S.A. · 36 participants
📍 Czechia
2026-525780-41-00 on CTIS ↗
Phase II Otorhinolaryngologic Diseases Authorised 02/06/2026
Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers
patients with head and neck squamous cell carcinoma (HNSCC)
Fakultni Nemocnice Kralovske Vinohrady · 40 participants
📍 Czechia
2025-524720-22-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 02/06/2026
Randomized, open-label, multiple dose, two-period, two-treatment, cross-over pharmacodynamic study in healthy male and female participants under fasting conditions.
Pharmacodynamic study under fasting condition.
Adamed Pharma S.A. · 42 participants
📍 Czechia
2026-526556-31-00 on CTIS ↗
Phase I Musculoskeletal Diseases Authorised 02/06/2026
An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
treatment of myasthenia gravis
Vianex S.A. · 44 participants
📍 Czechia
2025-524219-35-00 on CTIS ↗
Phase III Neoplasms Authorised 01/06/2026
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
Treatment-naїve mantle cell lymphoma (MCL)
Innocare Pharma Inc. · 102 participants
📍 Poland · France · Czechia · Spain · Romania
2025-524241-27-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 29/05/2026
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles · 86 participants
📍 Germany · France · Czechia · Netherlands · Spain
2024-516570-30-00 on CTIS ↗
Phase III Neoplasms Authorised 29/05/2026
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
Myelofibrosis
Novartis Pharma AG · 173 participants
📍 Belgium · Germany · Austria · Poland · Spain · Italy · Netherlands · Czechia · France
2025-523555-66-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
Cystic fibrosis
Vertex Pharmaceuticals Inc. · 80 participants
📍 Spain · Sweden · Germany · Italy · Belgium · Czechia · Ireland · Portugal · Netherlands · France · Denmark
2025-523400-72-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 28/05/2026
Optimising the protocol of labour induction using misoprostol – randomised open-label clinical trial (OPTIMISO)
Labour induction
Fakultni Nemocnice Brno · 200 participants
📍 Czechia
2026-525770-19-00 on CTIS ↗
Phase III Immune System Diseases Authorised 27/05/2026
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
Moderately to Severely Active Crohn’s Disease
Janssen Cilag International · 302 participants
📍 Slovakia · Germany · Denmark · France · Spain · Italy · Netherlands · Belgium · Poland · Sweden · Austria · Czechia · Hungary
2025-521590-13-00 on CTIS ↗
Phase II Mental Disorders Authorised 27/05/2026
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Maplight Therapeutics Inc. · 85 participants
📍 Italy · Poland · Czechia · Portugal · Bulgaria · France · Slovakia · Romania · Hungary
2025-521757-16-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 26/05/2026
A study comparing different dosage forms of midazolam and how they are taken up in the body.
Bioavailability Study under Fasting Conditions
MIDAS Pharma GmbH · 16 participants
📍 Czechia
2025-524999-37-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 22/05/2026
Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers
Parkinson disease
Orion Corporation · 40 participants
📍 Czechia
2026-525448-14-00 on CTIS ↗
Phase II Metabolism Authorised 21/05/2026
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
Adult patients with primary mitochondrial disease
Pharming Technologies B.V. · 117 participants
📍 Belgium · Germany · Czechia · Spain · Denmark · Italy · France
2025-524367-20-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 20/05/2026
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib
Chronic Spontaneous Urticaria
Novartis Pharma AG · 154 participants
📍 Germany · Spain · France · Poland · Bulgaria · Czechia
2025-524078-40-00 on CTIS ↗
Phase III Immune System Diseases Authorised 20/05/2026
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
Hidradenitis Suppurativa (HS)
Novartis Pharma AG · 307 participants
📍 Portugal · Greece · Germany · Hungary · France · Spain · Bulgaria · Slovakia · Poland · Czechia · Belgium · Italy
2025-523259-72-00 on CTIS ↗
Phase II Immune System Diseases Authorised 19/05/2026
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Rheumatoid arthritis
Elevara Medicines Limited · 95 participants
📍 Czechia · Bulgaria · Hungary · Netherlands · Poland · Spain
2025-524005-32-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 19/05/2026
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding
VarmX B.V. · 443 participants
📍 Belgium · Germany · Italy · France · Czechia · Bulgaria · Hungary · Spain · Netherlands · Poland · Austria · Estonia · Romania · Portugal · Lithuania
2025-521632-12-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 18/05/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC · 398 participants
📍 Italy · Finland · Bulgaria · Greece · Belgium · Estonia · Portugal · Spain · Germany · France · Czechia · Slovakia · Romania · Croatia · Poland · Austria · Netherlands · Denmark · Sweden · Hungary
2025-524316-11-00 on CTIS ↗
Phase III Neoplasms Authorised 15/05/2026
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 265 participants
📍 Portugal · Norway · Sweden · Bulgaria · France · Belgium · Austria · Germany · Finland · Poland · Romania · Netherlands · Spain · Italy · Hungary · Czechia
2025-523586-18-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 14/05/2026
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/refractory primary central nervous system lymphoma
Deciphera Pharmaceuticals Inc. · 74 participants
📍 Czechia · Germany · Italy · Belgium · Spain · Poland · Austria · France
2025-523389-26-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
advanced or metastatic extrapulmonary neuroendocrine carcinoma
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 144 participants
📍 Portugal · Spain · Poland · Sweden · Italy · Czechia · France · Netherlands · Finland · Denmark · Austria · Germany · Belgium · Norway
2025-523869-22-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 13/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or Overweight and Type 2 Diabetes
F. Hoffmann-La Roche AG · 551 participants
📍 Germany · Romania · Czechia · Poland · Hungary · France · Spain · Italy
2025-523106-32-00 on CTIS ↗
Phase II Neoplasms Authorised 12/05/2026
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
Esophageal squamous cell carcinoma
Merck Sharp & Dohme LLC · 12 participants
📍 Czechia · Germany · France · Norway
2026-525213-31-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 12/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
severe uncontrolled asthma
Generate Biomedicines Inc. · 271 participants
📍 Latvia · Hungary · Bulgaria · Romania · Portugal · Netherlands · Croatia · Germany · Greece · Czechia
2025-521950-41-00 on CTIS ↗
Phase III Neoplasms Authorised 12/05/2026
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 295 participants
📍 Czechia · Sweden · Poland · Netherlands · Greece · Latvia · Finland · Norway · Belgium · Austria · Portugal · Romania · Italy · Estonia · France · Ireland · Germany · Spain · Bulgaria · Hungary
2025-520565-51-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 12/05/2026
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
Psoriatic Arthritis
Takeda Development Center Americas Inc. · 638 participants
📍 Germany · Belgium · Spain · Czechia · Croatia · Portugal · Poland · Latvia · Bulgaria · France · Estonia · Hungary · Italy
2025-522586-30-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 11/05/2026
A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)
Dyslipidemia at High to Very High Cardiovascular Risk
A. Menarini International Licensing S.A. · 338 participants
📍 Spain · Poland · Netherlands · Italy · Slovakia · Czechia · Germany
2025-524265-24-00 on CTIS ↗
Phase III Immune System Diseases Authorised 11/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.
Octapharma Pharmazeutika Produktionsgesellschaft mbH · 215 participants
📍 Czechia · Lithuania · Greece · Poland · Germany · Latvia · Bulgaria · Italy
2025-522854-37-00 on CTIS ↗
Phase III Neoplasms Authorised 11/05/2026
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms
Eli Lilly & Co. · 486 participants
📍 Netherlands · Hungary · France · Austria · Poland · Italy · Denmark · Romania · Greece · Norway · Czechia · Belgium · Spain · Ireland · Germany
2025-522255-25-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 11/05/2026
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
Chronic rhinosinusitis with nasal polyps
Sanofi-Aventis Recherche & Developpement · 146 participants
📍 Germany · Netherlands · Portugal · Denmark · Sweden · Finland · France · Spain · Austria · Italy · Hungary · Romania · Belgium · Czechia · Poland
2025-522983-33-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 07/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight Without Type 2 Diabetes
F. Hoffmann-La Roche AG · 754 participants
📍 Poland · Hungary · France · Belgium · Italy · Netherlands · Czechia · Germany · Spain
2025-523104-71-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 05/05/2026
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects
short-term treatment of insomnia
Orion Corporation · 24 participants
📍 Czechia
2025-524376-36-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/05/2026
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
Persistent Corneal Epithelial Defect (PCED)
Dompe' Farmaceutici S.p.A. · 91 participants
📍 Czechia · Italy · Netherlands · Poland · Germany · Spain · Hungary · France
2025-523443-35-00 on CTIS ↗
Phase II Immune System Diseases Authorised 05/05/2026
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Graves’ Disease
Immunovant Sciences GmbH · 128 participants
📍 Italy · Greece · Germany · Hungary · Poland · Czechia · Netherlands · Spain · Belgium · Bulgaria · Latvia
2025-524001-33-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes
Obesity
Kailera Therapeutics Inc. · 612 participants
📍 Bulgaria · Hungary · Spain · Germany · Czechia · Poland
2025-523486-17-00 on CTIS ↗
Phase III Immune System Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Janssen Cilag International · 271 participants
📍 Denmark · Hungary · Portugal · Italy · Norway · Greece · Slovakia · Czechia · France · Poland · Bulgaria · Germany · Spain · Romania · Finland
2025-523552-31-00 on CTIS ↗
Phase II Eye Diseases Authorised 04/05/2026
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
Geographic atrophy secondary to age-related macular degeneration
Novartis Pharma AG · 142 participants
📍 Bulgaria · Romania · Germany · Czechia · Spain · Poland · Italy · Hungary · France
2025-523704-77-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes
Obesity
Kailera Therapeutics Inc. · 626 participants
📍 Hungary · Poland · Bulgaria · Germany · Czechia · Spain
2025-523510-87-00 on CTIS ↗
Phase III Immune System Diseases Authorised 04/05/2026
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy
IgA nephropathy
Novartis Pharma AG · 69 participants
📍 Belgium · France · Czechia · Croatia · Greece · Germany · Italy · Spain
2024-519638-22-00 on CTIS ↗
Phase III Neoplasms Authorised 04/05/2026
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC · 311 participants
📍 Denmark · Spain · Netherlands · Germany · France · Czechia · Poland · Italy · Greece
2024-516993-31-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 28/04/2026
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc. · 94 participants
📍 Spain · Poland · Italy · Belgium · Latvia · Denmark · Czechia · Germany · France · Netherlands · Portugal · Ireland · Greece
2024-520218-23-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations
Merck Sharp & Dohme LLC · 37 participants
📍 Czechia · Spain · Poland · Belgium · Finland · Germany · France · Netherlands · Hungary · Denmark
2025-524160-38-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases
F. Hoffmann-La Roche AG · 237 participants
📍 Belgium · France · Italy · Austria · Romania · Poland · Portugal · Czechia · Germany · Spain · Hungary
2025-524498-17-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 28/04/2026
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
Cinclus Pharma Holding AB (publ) · 96 participants
📍 Hungary · Germany · Romania · Bulgaria · Czechia · Poland
2025-522750-39-00 on CTIS ↗
Phase I Eye Diseases Authorised 28/04/2026
Safety of stem cells in treatmemt of retinal diseases.
Retinal degenerative diseases
Bioinova a.s. · 10 participants
📍 Czechia
2023-503573-38-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
Ovarian cancer
Merck Sharp & Dohme LLC · 349 participants
📍 Norway · Ireland · Spain · Greece · France · Poland · Denmark · Austria · Hungary · Belgium · Czechia · Finland · Germany · Italy · Sweden
2023-508047-40-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome
Epygenix Therapeutics Inc. · 98 participants
📍 Italy · Spain · Hungary · Romania · Czechia · Poland
2025-522552-20-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia
Agitation in Alzheimer's Disease Dementia
Exciva GmbH · 222 participants
📍 Italy · Slovakia · Spain · Poland · Czechia · Germany
2024-517388-22-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 27/04/2026
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)
Cancer-Associated Thrombosis (CAT).
Regeneron Pharmaceuticals Inc. · 324 participants
📍 Belgium · Czechia · France · Romania · Germany · Poland · Bulgaria · Spain
2024-519298-21-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 27/04/2026
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A. · 103 participants
📍 Belgium · Germany · Italy · Czechia · Bulgaria · Netherlands · France · Portugal · Poland · Spain · Romania
2024-514246-37-00 on CTIS ↗
Phase II Neoplasms Authorised 27/04/2026
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
AstraZeneca AB · 63 participants
📍 Italy · Austria · Spain · Ireland · Czechia · Poland
2024-518858-17-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/04/2026
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
Novartis Pharma AG · 21 participants
📍 Italy · Spain · Germany · Netherlands · France · Denmark · Czechia
2025-522019-40-00 on CTIS ↗
Phase I Not possible to specify Authorised 24/04/2026
Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
No medical condition
Laboratorios Cinfa S.A. · 32 participants
📍 Czechia
2026-526102-33-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 21/04/2026
J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Obesity, Overweight
Eli Lilly & Co. · 286 participants
📍 Spain · Romania · Belgium · Czechia
2025-523659-73-00 on CTIS ↗
Phase I Immune System Diseases Authorised 21/04/2026
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myopathy
Seropositive autoimmune disease: Sjogren’s disease or idiopathic inflammatory myopathy
Ouro Medicines Limited · 8 participants
📍 Czechia
2025-524100-29-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
treatment-naive Chronic Lymphocytic Leukemia
BeOne Medicines I GmbH · 186 participants
📍 Netherlands · Poland · Italy · Germany · Spain · Romania · Czechia · France · Sweden
2025-524366-21-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 20/04/2026
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Homeostatic iron regulator gene-related hereditary hemochromatosis
CSL Behring LLC · 50 participants
📍 Austria · Poland · Spain · Germany · France · Ireland · Romania · Belgium · Italy · Czechia · Netherlands
2025-523793-16-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG · 18 participants
📍 Spain · Hungary · Czechia · France · Italy · Belgium
2024-520125-36-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
Eli Lilly & Co. · 197 participants
📍 Italy · Poland · Denmark · Czechia · France · Hungary · Germany · Netherlands · Spain
2025-522855-25-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 17/04/2026
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
HFpEF or HFmrEF and obesity
Novo Nordisk A/S · 1992 participants
📍 Denmark · Greece · Bulgaria · Italy · Netherlands · Spain · Poland · Czechia · Germany · France
2025-523717-29-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/04/2026
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
Advanced HR+/HER- breast cancer
Novartis Pharma AG · 55 participants
📍 Italy · Germany · France · Czechia · Denmark · Spain
2025-521911-38-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 16/04/2026
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)
Obesity
Metsera Inc. · 919 participants
📍 Czechia · Bulgaria · Slovakia · Spain · Hungary · Germany · Romania · Poland
2025-523975-48-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/czechia (Accessed: 6 July 2026).

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker.